-DOCSTART- -X- O
T10B9.1A-31 -X- _ B-Intervention
/ -X- _ I-Intervention
MEDI-500 -X- _ I-Intervention
is -X- _ O
a -X- _ O
nonmitogenic -X- _ O
immunoglobulin -X- _ O
M -X- _ O
kappa -X- _ O
murine -X- _ O
monoclonal -X- _ B-Intervention
antibody -X- _ I-Intervention
( -X- _ I-Intervention
mAb -X- _ I-Intervention
) -X- _ I-Intervention
directed -X- _ O
against -X- _ O
the -X- _ O
alpha-beta -X- _ O
( -X- _ O
αβ -X- _ O
) -X- _ O
heterodimer -X- _ O
of -X- _ O
the -X- _ O
T-lymphocyte -X- _ O
receptor -X- _ O
complex. -X- _ O
The -X- _ O
hybridoma -X- _ O
was -X- _ O
first -X- _ O
produced -X- _ O
by -X- _ O
fusing -X- _ O
spleen -X- _ O
cells -X- _ O
from -X- _ O
BALB -X- _ O
/ -X- _ O
C -X- _ O
mice -X- _ O
immunized -X- _ O
with -X- _ O
human -X- _ O
peripheral -X- _ O
blood -X- _ O
T-lymphocytes -X- _ O
with -X- _ O
SP2 -X- _ O
/ -X- _ O
O-Ag14 -X- _ O
mutant -X- _ O
myeloma -X- _ O
cells. -X- _ O
The -X- _ O
mAb -X- _ B-Intervention
is -X- _ O
produced -X- _ O
and -X- _ O
purified -X- _ O
using -X- _ O
multistep -X- _ O
ion -X- _ O
exchange -X- _ O
and -X- _ O
molecular -X- _ O
sieve -X- _ O
chromatography -X- _ O
protocols. -X- _ O
T10B9 -X- _ B-Intervention
has -X- _ O
been -X- _ O
used -X- _ O
successfully -X- _ O
to -X- _ O
treat -X- _ B-Outcome
acute -X- _ I-Outcome
cellular -X- _ I-Outcome
rejection -X- _ I-Outcome
in -X- _ I-Outcome
renal -X- _ I-Outcome
transplantation -X- _ I-Outcome
and -X- _ I-Outcome
as -X- _ I-Outcome
an -X- _ I-Outcome
immunosuppression -X- _ I-Outcome
induction -X- _ I-Outcome
agent -X- _ I-Outcome
in -X- _ I-Outcome
heart -X- _ I-Outcome
and -X- _ I-Outcome
simultaneous -X- _ I-Outcome
kidney-pancreas -X- _ I-Outcome
transplantation. -X- _ I-Outcome
Because -X- _ O
T10B9 -X- _ B-Intervention
is -X- _ O
nonmitogenic -X- _ O
and -X- _ O
causes -X- _ O
minimal -X- _ O
cytokine -X- _ O
release -X- _ O
, -X- _ O
both -X- _ O
treatment -X- _ B-Outcome
of -X- _ I-Outcome
rejection -X- _ I-Outcome
and -X- _ I-Outcome
induction -X- _ I-Outcome
of -X- _ I-Outcome
immunosuppression -X- _ I-Outcome
were -X- _ I-Outcome
accomplished -X- _ I-Outcome
with -X- _ I-Outcome
significantly -X- _ I-Outcome
fewer -X- _ I-Outcome
and -X- _ I-Outcome
milder -X- _ I-Outcome
untoward -X- _ I-Outcome
effects -X- _ I-Outcome
( -X- _ I-Outcome
cytokine -X- _ I-Outcome
release -X- _ I-Outcome
syndrome -X- _ I-Outcome
) -X- _ I-Outcome
than -X- _ O
its -X- _ B-Comparision
comparator -X- _ I-Comparision
OKT3. -X- _ I-Comparision
Since -X- _ O
T10B9 -X- _ B-Intervention
is -X- _ O
directed -X- _ O
against -X- _ O
the -X- _ O
αβ -X- _ O
heterodimer -X- _ O
of -X- _ O
the -X- _ O
CD3 -X- _ O
epitope -X- _ O
, -X- _ O
it -X- _ O
spares -X- _ B-Outcome
the -X- _ I-Outcome
gamma -X- _ I-Outcome
delta -X- _ I-Outcome
( -X- _ I-Outcome
γδ -X- _ I-Outcome
) -X- _ I-Outcome
region. -X- _ I-Outcome
These -X- _ O
gamma -X- _ O
delta -X- _ O
( -X- _ O
γδ -X- _ O
) -X- _ O
T -X- _ O
cells -X- _ O
have -X- _ O
a -X- _ O
unique -X- _ O
role -X- _ O
in -X- _ O
the -X- _ O
immune -X- _ O
response -X- _ O
controlling -X- _ O
many -X- _ O
serious -X- _ O
human -X- _ O
diseases -X- _ O
and -X- _ O
perhaps -X- _ O
facilitating -X- _ O
the -X- _ O
development -X- _ O
of -X- _ O
immunologic -X- _ O
tolerance. -X- _ O
T10B9 -X- _ B-Intervention
has -X- _ O
a -X- _ O
relatively -X- _ O
short -X- _ O
duration -X- _ O
of -X- _ O
action -X- _ O
, -X- _ O
depleting -X- _ B-Outcome
T -X- _ I-Outcome
cells -X- _ I-Outcome
for -X- _ I-Outcome
only -X- _ I-Outcome
10 -X- _ I-Outcome
to -X- _ I-Outcome
14 -X- _ I-Outcome
days -X- _ I-Outcome
, -X- _ O
unlike -X- _ B-Comparision
the -X- _ I-Comparision
protracted -X- _ I-Comparision
depletion -X- _ I-Comparision
seen -X- _ I-Comparision
with -X- _ I-Comparision
thymoglobulin -X- _ I-Comparision
and -X- _ I-Comparision
Campath-1H. -X- _ I-Comparision
There -X- _ O
is -X- _ O
no -X- _ B-Outcome
B-lymphocyte -X- _ I-Outcome
depletion -X- _ I-Outcome
with -X- _ I-Outcome
T10B9 -X- _ I-Outcome
as -X- _ O
there -X- _ O
is -X- _ O
with -X- _ O
both -X- _ O
of -X- _ O
the -X- _ O
aforementioned -X- _ O
reagents. -X- _ O
The -X- _ O
lack -X- _ B-Outcome
of -X- _ I-Outcome
prolonged -X- _ I-Outcome
lymphocyte -X- _ I-Outcome
depletion -X- _ I-Outcome
may -X- _ I-Outcome
account -X- _ I-Outcome
for -X- _ I-Outcome
less -X- _ I-Outcome
infection -X- _ I-Outcome
observed -X- _ I-Outcome
with -X- _ I-Outcome
T10B9 -X- _ I-Outcome
treatment -X- _ I-Outcome
. -X- _ O

